Hepatitis C virus genotype 1 infection: Prevalence of NS5A and NS5B resistance‐associated substitutions in naïve patients from Argentina
- 5 July 2019
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 91 (11) , 1970-1978
Abstract
Direct acting antiviral (DAA) therapy against hepatitis C virus (HCV) increases sustained virologic response rates. Nevertheless, drug resistance has occasionally been associated with failure to DAA. However, the information about the prevalence of NS5A and NS5B resistance‐associated substitutions (RASs) in Argentina is very scarce. In this study, we determine the prevalence of NS5A and NS5B resistances to treatment in Argentinean DAA treatment‐naïve patients chronically infected with genotype 1 (HCV‐1). In this retrospective cross‐sectional study, 108 HCV‐1‐infected patients were studied. RASs in NS5A and NS5B were analyzed by Sanger at baseline and phylogenetic analysis was performed. NS5A and NS5B RASs were detected in 25.8% and 6.3% of the analyzed sequences, respectively. The most frequent primary RASs for NS5A were L31M (7.5%) and Y93H (3.2%) and for NS5B was L159F (3.8%). No association between the presence of RASs and the outcome of DAA treatment was found in this study. Additionally, most of the Argentinean samples were randomly distributed among sequences around the world in the phylogenetic analysis. Only one significant Argentinean cluster was observed in both regions but without any particular RASs pattern. Baseline RASs in NS5A and NS5B were frequently observed in HCV‐1‐infected patients from Buenos Aires, Argentina but not related to treatment outcome. No clusters related to RASs transmission were observed in the phylogenetic analysis. The frequency of RASs detected in this study supports the need for more molecular epidemiology studies on RASs to adjust local treatment guidelines with the incorporation of autochthonous data.Keywords
Funding Information
- Agencia Nacional de Promoción Científica y Tecnológica ((PICT 2013‐1268 and PICT 2017‐2429))
- Fundación Alberto J. Roemmers (N/A)
This publication has 42 references indexed in Scilit:
- Sofosbuvir and velpatasvir with or without voxilaprevir in direct‐acting antiviral‐naïve chronic hepatitis C: patient‐reported outcomes from POLARIS 2 and 3Alimentary Pharmacology & Therapeutics, 2017
- Prevalence of hepatitis C virus infection according to the year of birth: identification of risk groupsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2017
- Geno2pheno[HCV] – A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral AgentsPLOS ONE, 2016
- The importance of resistance to direct antiviral drugs in HCV infection in clinical practiceJournal of Hepatology, 2016
- Direct‐acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN‐free treatment and future perspectivesLiver International, 2016
- Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and DasabuvirAntimicrobial Agents and Chemotherapy, 2015
- Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical TrialsClinical Infectious Diseases, 2014
- Update on hepatitis C virus resistance to direct-acting antiviral agentsAntiviral Research, 2014
- Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C VirusAntimicrobial Agents and Chemotherapy, 2012
- Telaprevir for Retreatment of HCV InfectionNew England Journal of Medicine, 2011